Acute Myeloid Leukemia Clinical Trial

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Summary

This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

View Full Description

Full Description

The study will include AML participants with measurable disease, for whom standard-of-care (SOC) is not available. Two Groups of AML participants will be included in this study:

Group I participants will have hematologic relapse/refractory disease defined as participants not in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi).
Group II participants will have molecular relapse/persistent disease (participants with a CR or CRi, and a positive MRD based on local multi-parameter flow cytometry (MFC) or molecular assessment).

The study consists of three parts:

Part A (single-participant dose escalation cohorts) - single participants from Group I will receive increment-based escalating doses until a Grade >=2 AE related to RO7283420 or a clear pharmacodynamic effect
Part B (multiple-participant dose escalation cohorts) - multiple-participant cohorts of >=3 participants will be enrolled for dose escalation for Group I and Group II independently.
Part C (dose expansion) - participants will receive the respective identified RP2D for that group.

The treatment period for each participant will be up to 7 months with a maximum number of cycles depending on the dosing frequency the participant receives. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, every-2-weeks (Q2W), or once-a-week (QW) dosing regimens, respectively. Additional 3, 5, or 9 cycles may be administered for the Q3W, Q2W, and QW dosing regimens, respectively, in case the participants have achieved at least partial remission (PR).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

With confirmed diagnosis of primary or secondary AML according to WHO classification 2016, with measurable disease. Eligible participants need to have received standard-of-care (SOC) and have no other SOC options available Participants who are not willing to receive SOC will be not eligible. Two groups of participants (Group I - hematologic relapsed/refractory and Group II - molecular relapsed/refractory) will be included
Participants who have received hematopoietic stem cell transplant (HSCT) must have the HSCT performed ≥ 90 days prior to the first dose of RO7283420 on Cycle 1 Day 1, having demonstrated hematological engraftment and do not have an active Graft versus Host Disease, not requiring immunosuppressive treatment (including but not limited to cyclosporine, tacrolimus, sirolimus, and mycophenolate), which must be stopped at least 28 days prior to the first dose of RO7283420 on Cycle 1 Day 1
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Peripheral blast counts =< 20,000/mm3 on Cycle 1 Day 1 prior to the first dosing
Confirmed genotype of HLA-A*02
Adequate renal (a creatinine clearance of >=50 mL/min as calculated according to the Cockroft-Gault formula) and adequate liver test results
Male or female participants agree to use contraception and the abstinence requirements to prevent exposure of an embryo to the study treatment

Exclusion Criteria:

Acute promyelocytic leukemia (APL)
Core Binding Factor (CBF)-AML Note: participants with r/r CBF-AML after at least 2 salvage attempts can be enrolled into the study
Group II only: participants with normal karyotype and a favorable molecular profile according to ELN guideline 2017
Participants with active bacterial, fungal or viral infection considered by the Investigator to be clinically uncontrolled or of unacceptable risk upon the induction of neutropenia (i.e. participants who are or should be on antimicrobial agents for the treatment of active infection)
Grade >= 2 glomerular proteinuria at screening or on Cycle 1 Day 1 prior to the first dosing.
Another primary malignancy (other than AML) that requires active therapy. Adjuvant hormonal therapy is allowed
Clinical evidence or history of central nervous system (CNS) leukemia
Presence of extramedullary disease at screening
Current or past history of CNS disease, such as stroke, CNS inflammation, epilepsy, CNS vasculitis, or neurodegenerative disease
Participants who have a history of clinically significant liver disease, including liver cirrhosis (e.g. Child-Pugh class B and C) or participants who have a history of active or chronic infectious hepatitis unless serology demonstrates clearance of infection
Participants who might refuse to receive blood products and/or have known hypersensitivity to any of the components of RO7283420, tocilizumab, or dasatinib

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

220

Study ID:

NCT04580121

Recruitment Status:

Recruiting

Sponsor:

Hoffmann-La Roche

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 25 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States
UC Davis Comprehensive Cancer Center
Sacramento California, 95817, United States
Washington University; Wash Uni. Sch. Of Med
Saint Louis Missouri, 63110, United States
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Peter MacCallum Cancer Centre; Medical Oncology
Melbourne Victoria, 3000, Australia
The Alfred
Melbourne Victoria, 3124, Australia
Princess Margaret Cancer Center
Toronto Ontario, M5G 1, Canada
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT
København Ø , 2100, Denmark
Institut Paoli Calmettes; Departement D' Onco-Hematologie
Marseille , 13273, France
Hopital De Haut Leveque; Hematologie Clinique
Pessac , 33604, France
Universitätsklinikum "Carl Gustav Carus"; Medizinische Klinik und Poliklinik I
Dresden , 01307, Germany
Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III
München , 81377, Germany
ASST PAPA GIOVANNI XXIII; Ematologia
Bergamo Lombardia, 24127, Italy
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
Rozzano Lombardia, 20089, Italy
Ospedale Santa Chiara; Unita Operativa Di Ematologia
Pisa Toscana, 56100, Italy
Institut Catala d´Oncologia Hospital Germans Trias i Pujol
Badalona Barcelona, 08916, Spain
Hospital Universitari Vall d'Hebron; Servicio de Hematologia
Barcelona , 08035, Spain
Hospital Clínic i Provincial; Servicio de Hematología y Oncología
Barcelona , 08036, Spain
Hospital Univ. 12 de Octubre; Servicio de Hematologia
Madrid , 28041, Spain
Hospital Universitario la Fe; Servicio de Hematologia
Valencia , 46026, Spain
China Medical University Hospital; Oncology and Hematology
Taichung , 404, Taiwan
National Cheng Kung University Hospital; Oncology
Tainan , 00704, Taiwan
National Taiwan Universtiy Hospital; Division of Hematology
Taipei , 100, Taiwan
Churchill Hospital
Oxford , OX3 7, United Kingdom
Royal Marsden NHS Foundation Trust
Sutton , SM2 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

220

Study ID:

NCT04580121

Recruitment Status:

Recruiting

Sponsor:


Hoffmann-La Roche

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.